Objective: To investigate the value of baseline anti-mutated citrullinated vimentin (MCV) antibody for predicting one-year radiographic progression in patients with rheumatoid arthritis (RA). Methods: Consecutive RA patients were recruited from November 2014 to July 2018 at Department of Rheumatology, Sun Yat-sen Memorial Hospital, Clinical data were collected including disease activity score in 28 joints with four variables including C-reactive protein (CRP).Serum anti-MCV antibody at baseline was detected by enzyme-linked immunosorbent assay. X ray assessment of both hands/wrists was performed and assessed according to the Sharp/van der Heijde modified score (mTSS) at baseline and the 12th month. Univariate and multivariate logistic regression analyses were used to identify the risk factors for one-year radiographic progression. Results: Among 220 RA patients recruited, the positive rate of anti-MCV antibody at baseline was 77.7%. Compared with those with negative anti-MCV antibody, RA patients with positive anti-MCV antibody had higher disease activity score in 28 joints with four variables induding CRP [3.8 (2.4, 5.0) vs. 3.1 (2.1, 4.0), P=0.007], more physical dysfunction (21.6% vs. 8.2%, P=0.033) and higher radiographic indicators including mTSS [11 (2, 27) vs. 4 (1, 10), P=0.003], joint space narrowing [JSN, 4 (0, 14) vs. 2 (0, 6), P=0.024] and joint erosion[JE, 5 (1, 18)vs. 3 (0, 5), P=0.003]. After one-year follow-up, sixty-six RA patients (30.0%) developed radiographic progression, the percentage of whom was significantly higher in positive anti-MCV group than that in negative anti-MCV group (33.9% vs.16.3%, P=0.018). Multivariate logistic regression analysis suggested that positive anti-MCV antibody at baseline was an independent risk factor for one-year radiographic progression (OR=2.341, 95%CI 1.002-5.469). Conclusion: Positive anti-MCV antibody at baseline predicts one-year radiographic progression in RA patients. In the future, anti-MCV antibody can be used not only as a supplementary laboratory marker, but also in disease activity assessment and prognosis prediction for RA.
目的： 探讨抗突变型瓜氨酸波形蛋白（MCV）抗体对类风湿关节炎（RA）患者1年关节影像学进展的预测价值。 方法： 选2014年11月至2018年7月中山大学孙逸仙纪念医院风湿免疫科门诊和住院的RA患者，收集患者的临床资料，包括基于C反应蛋白的28个关节疾病活动度评分（DAS28-CRP）等。检测患者抗MCV抗体等。随访1年，采用改良Sharp评分总分（mTSS）进行影像学评估。采用单因素或多因素logistic回归分析1年影像学进展的危险因素。 结果： 共入选220例RA患者，其中171例（77.7%）患者抗MCV抗体阳性。与抗MCV抗体阴性者比，阳性者DAS28-CRP［3.8 （2.4， 5.0） 比 3.1 （2.1， 4.0）， P=0.007］、出现功能障碍的比例［37例（21.6%） 比 4例（8.2%）， P=0.033］、mTSS［11 （2， 27）分 比 4 （1， 10）分， P=0.005］、关节间隙狭窄评分［4 （0， 14）分 比 2 （0， 6）分， P=0.024］、关节侵蚀评分［5 （1， 18）分 比 3 （0， 5）分， P=0.003］均明显升高。随访1年后，66例（30.0%）RA患者出现关节影像学进展，基线抗MCV抗体阳性者出现影像学进展的比例明显高于阴性者［58例（33.9%）比 8例（16.3%）， P=0.018］。多因素logistic回归分析显示，基线抗MCV抗体阳性（OR=2.341， 95%CI 1.002~5.469，P=0.049）是1年关节影像学进展的独立危险因素。 结论： 基线抗MCV抗体阳性是RA患者1年关节影像学进展的预测因素，未来其不仅能作为RA诊断的补充指标，亦可用于RA病情评估及预测预后。.